Navigation Links
Boston equity firm becomes majority owner of Cedarburg-based Mortgagebot

Cedarburg, Wis. -- Spectrum Equity Investors of Boston will become the new majority owner of Cedarburg-based Mortgagebot, a national provider of technology to mortgage lenders.

Spectrum on Wednesday announced that it has completed an $84 million recapitalization of Mortgagebot.

Following ......

Full article >>>
'"/>

Source:wistechnology.com By WTN News 09/28/05


Page: 1 2

Related biology technology :

1. Wicab to present BrainPort at Boston conference
2. Boston entrepreneur to enliven Milwaukee angel group
3. The birth of biotech: San Francisco, Boston, Geneva or Chicago?
4. Of private equity, research, and drug development
5. Daugherty becomes CTO of Great Lakes BioFuels
6. Historic observatory becomes hot property on Lake Geneva
7. DataPod becomes BeInSync so you can, too
8. Top 20 big pharmas represent majority of world pharma market
9. Protein lab could prosper under new owner
10. Northwoods Software co-owner distills 30 years of business experience
11. Patent essentials for business owners: from patent to profit

Post Your Comments:
(Date:11/23/2009)...n a provocative new study, a University of Utah sc...s the major cause of global warming cannot be st...ociety builds the equivalent of one new nuclear po...here will be any substantial near-term departure f...de emission rates," says the new paper by Tim Garr...
(Date:11/23/2009)...PRNewswire-FirstCall/--PDLBioPharma,Inc.(PDL)(Nasd...vember27,2009astheex-dividenddateforits$200million...itizationtransactioncompletedonNovember2,2009.Thed...sofrecordontherecorddate,December1,2009.NASDAQhass...pershareofcommonstockforpurposesoftheex-dividendda...
(Date:11/23/2009)...-ImmuneDesignC or p.(IDC)announcedtodaythatDr.Bruc...erhasasuccessfultrackrec or dinbiotechnologyexecut...ratZymoGenetics,inSeattle,WAandChiefScientificOffi...o: http://www.newscom.com/cgi-bin/prnh/20091123/SF...ecutiveOfficercommented,"IamdelightedtowelcomeDr.B...
(Date:11/23/2009)...-FirstCall/--CornerstoneTherapeuticsInc.(Nasdaq: C...iring,developingandcommercializingsignificantprodu...ayannouncedthatCraigA.Collard,PresidentandChiefExe...the21stAnnualPiperJaffrayHealthCareConferenceat3:3...otelinNewYorkCity. ,, Aliveaudioandarchivedwebc...
Breaking Biology Technology:Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend 2Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director 2Cornerstone Therapeutics to Present at the 21st Annual Piper Jaffray Health Care Conference 2
...Management Changes Announced, NEW YORK, March 5 ...nnounced that the company,s Board of Directors,has...chief financial,officer, effective March 31, 2008....recting and managing the company,s fiscal operatio...the organization and its,subsidiaries. Andrew Bonf...
...se II study of 20 patients reported in Annals of O....,(CTI) (Nasdaq: CTIC ; MTA) today announced the ...lts of a limited phase II study of CHOP chemothera...d prednisone) followed by,administration of Zevali...0,years of age or older) with previously untreated...
...lbaum, assistant professor of electrical and compu... received the prestigious Faculty Early Career Dev...n for his pioneering research in the exciting next... This emerging field focuses on harnessing the mag...ctronics ranging from computers to cell phones tha...
Other Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4UD's Appelbaum wins NSF Career Award for research on silicon spintronics 2UD's Appelbaum wins NSF Career Award for research on silicon spintronics 3
(Date:11/24/2009)...rs to understanding how sounds associated with Nav...l or if they hear it at all. , The same type of...ses to detect flaws in the space shuttle,s behemot... peek inside the giant head of a whale. The scans ...of a whale,s hearing anatomy using a breakthrough ...
(Date:11/24/2009)...bby arteries from collapsing have been true life-s...onger needed -- once the arteries are strengthened... no choice but to leave them in place. , Prof. M...t of Biomedical Engineering has developed a new pa...re they,re needed, then dissolves. , "Our new co...
(Date:11/24/2009)... of Medical Toxicology (ACMT) have signed an agree...rnal of Medical Toxicology (JMT), the official jo...s previously published by the University of Pennsy...ogy , an international, peer-reviewed journal, is ... medical toxicology. The quarterly journal focuse...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2A coating for life 2Springer and the American College of Medical Toxicology to work together 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 1Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 2Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 3Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 4Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 5Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 6Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 7Cardium Completes Initial Patient Evaluation Period for MATRIX Phase 2b Excellarate Clinical Study 4896 8Carondelet St Marys Medical Plaza II Opens In Tucson 55314 1MicroRNA in human saliva may help diagnose oral cancer 9696 1
...ced a major expansion of a lingua franca used to d...s. The expansion provides terms that scientists c...hen a pathogenic or beneficial microbe encounters ...r developing new interventions for preventing infe...g or encouraging the presence of beneficial microb...
...s of other individuals in order to cooperate in co...we humans take for granted. But, according to evol... Institute in Germany, this ability is present in ...April issue of Current Directions in Psychological... gaze and face orientation to monitor others, beha...
...may explain why Graves?disease (GD) attacks the mu... bulge painfully from their sockets, as in the lat...s Stein Eye Institute and Harbor-UCLA Medical Cent...cells of GD patients?immune systems. Reported Mar... deepen understanding of how the autoimmune disord...
Other Biology News:Uniform language for describing genes of pathogenic and beneficial microbes 2Uniform language for describing genes of pathogenic and beneficial microbes 3Man's best friend lends insight into human evolution 2UCLA study uncovers clues for why Graves' disease attacks the eyes 2
Viraffinity 100 from Biotech Support Group
Tumor Suppressor Sampler Kit from BD Biosciences Pharmingen
Mouse Anti-Synapsin I Monoclonal Antibody, Unconjugated, Clone 223 from IMGENEX
Slide Chambers from Novagen
Biology Products: